Second Sight Medical Products Inc. (EYES) Stock Price Up 3.7%
Second Sight Medical Products Inc. (NASDAQ:EYES) shares rose 3.7% on Tuesday . The stock traded as high as $3.69 and last traded at $3.68, with a volume of 127,169 shares trading hands. The stock had previously closed at $3.55.
EYES has been the subject of several analyst reports. Zacks Investment Research downgraded shares of Second Sight Medical Products from a “hold” rating to a “sell” rating in a research note on Tuesday, April 26th. Rodman & Renshaw restated a “buy” rating and issued a $16.00 target price on shares of Second Sight Medical Products in a research note on Tuesday, July 26th.
The company’s market cap is $155.29 million. The company’s 50-day moving average price is $3.96 and its 200-day moving average price is $4.41.
Second Sight Medical Products (NASDAQ:EYES) last posted its quarterly earnings results on Thursday, July 28th. The medical device company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by $0.02. During the same period last year, the business earned ($0.12) earnings per share. The firm had revenue of $1.04 million for the quarter, compared to analyst estimates of $2.66 million. Second Sight Medical Products’s quarterly revenue was down 63.0% compared to the same quarter last year. Analysts predict that Second Sight Medical Products Inc. will post ($0.62) earnings per share for the current fiscal year.
In related news, Chairman Robert J. Greenberg sold 8,571 shares of the firm’s stock in a transaction that occurred on Thursday, June 2nd. The shares were sold at an average price of $4.10, for a total transaction of $35,141.10. Following the transaction, the chairman now owns 172,911 shares of the company’s stock, valued at $708,935.10. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Second Sight Medical Products, Inc is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.